Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.18

-2.5%

Dec 1 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (1749)	9/28/2000 8:52:00 PM
From: Spekulatius	Read Replies (1) of 52153

I have been in and out SUPG as well and do not hold a position either. Right now, they appear to be a better buy than MOGN, IMHO. SUPG certainly has a hype element but more disturbing to me is that Joe Rubinfeld has lost key people for the clinical trials. This may have to do with the fact that Joe seems to run a family business (his wife is heads the HR) and has a huge ego. The Rubitecan trials are however high powered and if they show a significant clinical, benefit this drug could become a blockbuster, due to its mild side effect profile.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next